BLDR three-lens brief
Evidence-based stock research on BLDR. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Underperforming SPY by 18.5pp over 30 days. · Trading at 1% of its 52-week range — deep in the lower band.
- Trading at 1% of its 52-week range — deep in the lower band.
- Underperforming SPY by 18.5pp over 30 days.
- Analyst mean target $97.95 — 30% above current (21 analysts).
- Debt-to-equity of 132.2 — balance-sheet-heavy.
BLDR closed at $75.28 (-0.58%) as of 2026-05-04. Market cap: $8.09B. P/E (trailing) 28.7. Positives: analyst mean target $97.95 — 30% above current (21 analysts).. Concerns: trading at 1% of its 52-week range — deep in the lower band.; underperforming SPY by 18.5pp over 30 days.. Last quarter: Revenue $3.29B, net income -$47.41M, free cash flow $640.90M.
Why three lenses on BLDR, not one.
A single reasoning model has blind spots it doesn’t know about. We examine BLDRacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/BLDR" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath BLDR brief"></iframe>